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Abstract
In order to assess the susceptibility of bank voles to chronic wasting disease (CWD), we inoculated voles carrying isoleucine
or methionine at codon 109 (Bv109I and Bv109M, respectively) with CWD isolates from elk, mule deer and white-tailed deer.
Efficient transmission rate (100%) was observed with mean survival times ranging from 156 to 281 days post inoculation.
Subsequent passages in Bv109I allowed us to isolate from all CWD sources the same vole-adapted CWD strain (Bv109ICWD),
typified by unprecedented short incubation times of 25–28 days and survival times of ,35 days. Neuropathological and
molecular characterisation of Bv109ICWD showed that the classical features of mammalian prion diseases were all
recapitulated in less than one month after intracerebral inoculation. Bv109ICWD was characterised by a mild and discrete
distribution of spongiosis and relatively low levels of protease-resistant PrPSc (PrPres) in the same brain regions. Despite the
low PrPres levels and the short time lapse available for its accumulation, end-point titration revealed that brains from
terminally-ill voles contained up to 108,4 i.c. ID50 infectious units per gram. Bv
109ICWD was efficiently replicated by protein
misfolding cyclic amplification (PMCA) and the infectivity faithfully generated in vitro, as demonstrated by the preservation
of the peculiar Bv109ICWD strain features on re-isolation in Bv109I. Overall, we provide evidence that the same CWD strain
was isolated in Bv109I from the three-cervid species. Bv109ICWD showed unique characteristics of ‘‘virulence’’, low PrPres
accumulation and high infectivity, thus providing exceptional opportunities to improve basic knowledge of the relationship
between PrPSc, neurodegeneration and infectivity.
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Introduction
Chronic wasting disease (CWD) of cervids belongs to the family
of transmissible spongiform encephalopathies (TSE) or prion
diseases, a group of fatal neurodegenerative pathologies affecting
animals and humans. They are characterised by spongiform
changes, gliosis and the deposition in the brain of a post-
translational misfolded isoform (PrPSc) of the host-encoded cellular
prion protein (PrPc). Prion diseases also include Creutzfeldt-Jakob
disease (CJD) of humans, scrapie of sheep and goats and bovine
spongiform encephalopathy (BSE) of cattle.
CWD is the only prion disease known to affect free-ranging wild
animals. It was first described in the United States in the late 1960s
[1]. Currently, CWD has been diagnosed in farmed and free-
ranging cervids in several areas of North America [2] and South
Korea, where it was accidentally imported from Canada [3]. The
disease has been documented in Rocky Mountain elk (Cervus
elaphus nelsoni), mule deer (Odocoileus hemionus), white-tailed deer
(Odocoileus virginianus) and moose (Alces alces) [4].
Epidemiological evidence indicates that CWD spreads naturally
with relative efficiency and recent trend analyses suggest that its
prevalence is increasing [5].
The development of laboratory models for CWD has long been
hampered by the very inefficient transmission of CWD to wild-
type mice [6]. Significant progress was made by the generation of
transgenic mice over-expressing cervid PrP [6,7,8,9,10,11]. CWD
has also been transmitted, albeit less efficiently, to transgenic mice
over-expressing mouse [12] or Syrian hamster PrP, as well as to
different hamster species [13]. Recently, CWD was successfully
transmitted to different species of North American wild rodents
[14] and ferrets [15].
In recent years, with the aim of developing new animal models
for prion diseases, we have studied the susceptibility of the bank
vole (Myodes glareolus) to a wide range of human and animal prion
diseases. Two lines of voles, one homozygous for methionine and
the other for isoleucine at codon 109 of PrP – here designated
Bv109M and Bv109I, respectively – were investigated. Bv109M
was shown to be susceptible to sporadic and genetic CJD [16,17],
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sheep scrapie [18,19], mouse- and hamster-adapted scrapie strains
[20,21,22], cattle and sheep BSE [16,22] and atypical BSE [22].
Overall susceptibility of Bv109I was found to be comparable to
that of the methionine-carrying line, although with differences
depending on the specific prion disease (unpublished data).
In the present study, we investigated the susceptibility of bank
voles to CWD. To this purpose, we inoculated Bv109M and
Bv109I with various CWD sources and found that CWD
replicated faster in Bv109I compared to Bv109M. We then
focused on the Bv109I line, which showed unprecedented short
survival times upon CWD adaptation. We describe a thorough
characterization of Bv109I-adapted CWD, showing that in spite of
their short survival time, high infectious titres accumulate in the
brains of affected animals. Furthermore, we provide evidence that
Bv109I-adapted CWD can be easily and faithfully replicated in
vitro by serial automated PMCA (saPMCA).
Results
Bank voles are susceptible to CWD isolates from three
cervid species
All CWD isolates transmitted with 100% attack rate and short
survival times in both Bv109I and Bv109M (Table 1). In some
groups survival times were not uniform. Indeed, while most of the
voles inoculated were clinically affected between 150 and 350 days
post-infection (d.p.i.), a minor proportion of voles showed much
longer survival times (Figure S1). Interestingly, Bv109I replicated
CWD faster than Bv109M, with 60–100 days shorter median
survival times (Figure S1). Conversely, SS7B, a scrapie isolate
previously shown to replicate efficiently in Bv109M [19], showed a
60 days longer median survival time in Bv109I. Overall, these data
demonstrate that the 109 methionine/isoleucine variation influ-
ences the susceptibility of voles in a strain dependent fashion and
that Bv109I is a fast model for CWD replication. We thus further
investigated the transmission features of CWD in the bank vole
line expressing isoleucine at codon 109.
Transmission features of CWD isolates in Bv109I
CWD isolates transmitted in Bv109I with mean survival times
ranging from 156 to 281 d.p.i. (Table 1). All isolates induced a
similar clinical picture. The onset of disease was characterised by
slight behavioural alterations; hypoactivity and hyporeactivity
were sometimes observed along with the disappearance of the
typical behaviour of hiding under the sawdust lining the cage.
Dorsal kyphosis, slight ataxia of the forelimb and occasional head
bobbing (upward movements of the head) accompanied the
progression of the disease. Overall, clinical signs were faint
compared with those previously observed in voles infected with
classical scrapie [19] and occasionally animals were found dead
because of the rapid progression to terminal stage. The three
isolates from white-tailed deer gave the shortest survival times,
ranging from 156 to 171 d.p.i., while the survival times were
slightly longer with isolates from elk and mule deer. As mentioned
above, individual voles showing a late clinical onset were observed
in CWD2, with two outliers at 414 and 656 d.p.i., in CWD3
(outlier at 805 d.p.i.) and CWD4 (792 d.p.i.) (Figure S1).
All infected voles showed moderate spongiform changes at brain
histopathology, accompanied by gliosis and neuronal loss
(Figure 1). All groups had a similar distribution of spongiform
degeneration, which mainly involved the superior colliculus, the
thalamus and, to a lesser extent, the cerebral cortex (Figure 2A). At
Author Summary
Chronic wasting disease (CWD) is a prion disease that
affects free-ranging and captive cervids and is expanding
increasingly in the USA and Canada. Animal models are of
key importance in the study of prion diseases but their
development for CWD has long been hampered by its very
inefficient transmission to wild-type mice. Significant
progress was made following the generation of transgenic
mice over-expressing cervid PrP. Here we show that the
bank vole (Myodes glareolus), a wild rodent species that we
demonstrated to be susceptible to many animal and
human prion diseases, is also very susceptible to CWD
from elk, mule deer and white-tailed deer. Adaptation of
CWD to bank vole led to the isolation of a prion strain with
peculiar characteristics: unprecedented short incubation
and survival times, respectively of 25–28 and ,35 days,
low PrPSc levels compared with other vole-adapted prion
strains and high infectious titre. These features were all
faithfully maintained upon the generation of this strain in
vitro by protein misfolding cyclic amplification. The
development of a model for prion diseases that led to
disease in less than one month accumulating high infec-
tious titres but low PrPSc levels, represents a significant
tool for investigating the still unclear relationship between
PrPSc, neurodegeneration and infectivity in prion diseases.
Table 1. Survival times of Bv109I and Bv109M after primary transmission of CWD.
Bv109I Bv109M
Survival time
(mean±SD)
No. of affected/No. of
inoculated
Survival time
(mean±SD)
No. of affected/No. of
inoculated
Elk CWD1 190625 16/16 280697 18/18
CWD2 2266123 18/18 278637 18/18
CWD4 2676232 7/7 253650 8/8
Mule deer CWD3 2816233 7/7 273654 7/7
White-tailed deer CWD5 156624 6/6 253629 11/11
CWD7 171618 5/5 259632 12/12
CWD8 169622 6/6 249616 12/12
Sheep SS7B 257642 15/17 188633* 14/14*
*Published in Di Bari et al., 2008.
doi:10.1371/journal.ppat.1003219.t001
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the cortical level, spongiosis preferentially involved the V and VI
deep layers (data not shown). Interestingly, spongiosis was not
observed in the cerebral cortex of four voles surviving longer than
400 d.p.i. (Figure S2), although they showed spongiform degen-
eration in the mesencephalon and diencephalon with a distribu-
tion similar to that of the other infected voles (data not shown).
PrPSc was readily detected in all infected voles by IHC, PET-blot
and WB. IHC showed punctate PrPSc deposition (Figure 1) restricted
to specific areas. The thalamus, substantia nigra, geniculate and
vestibular nuclei were the most involved areas. The hippocampus was
mostly spared, though some fibres of CA2 were occasionally found
positive. Overall, a topographical correlation between vacuolation,
neuronal loss and PrPSc deposition was observed (Figure 1).
Western blot analysis showed the typical three-band PrPres
pattern, which was similar in all CWD-infected voles (Figure 3).
Compared with elk and deer PrPres, bank vole CWD PrPres showed
a lower molecular mass of the unglycosylated band (Figure 3A),
similar to that reported in prairie voles infected with mule deer
CWD [23]. In keeping with the discrete brain distribution of PrPSc
observed by PET-blot or IHC, the overall level of PrPres detected in
brain homogenates was much lower than that usually found in vole-
adapted strains [16,19,22]. Direct comparison with Bv109I-adapted
SS7B showed that PrPres levels were at least 30 fold lower in Bv109I-
adapted CWD (Figure S3). In addition, the migration pattern was
different from that previously reported in bank vole TSEs, being
intermediate between scrapie and BSE (Figure 3B).
Figure 1. Histopathological and immunohistochemical analysis of Bv109I inoculated with Bv109ICWD. (A) Serial sections showing
neocortex (NC), hippocampus (Hp) and thalamus (Th), stained by haematoxylin and eosin and (B) by immunohistochemistry for PrPSc with SAF84
mAb - bar 500 mm. (C) and (D): magnification of the ventral thalamic nucleus (star) from (A) and (B), respectively - bar 50 mm.
doi:10.1371/journal.ppat.1003219.g001
Figure 2. Lesion profiles of Bv109I infected with CWD following primary transmission and third passage. Pathological phenotypes
observed after primary transmission and third passage are shown in (A) and (B), respectively. CWD1, 2 and 4 from elk, are shown in red, green and
violet lines with open circles, respectively; CWD3 from mule deer, in blue line and closed circles; CWD5, 6 and 7 from W-T deer in red, green and violet
dashed lines and closed triangles, respectively. Vole-adapted sheep scrapie is shown in black dashed line and closed circles. Brain-scoring areas are:
medulla (1), cerebellum (2), superior colliculus (3), hypothalamus (4), thalamus (5), hippocampus (6), septum (7), retrosplenial and adjacent motor
cortex (8), cingulate and adjacent motor cortex (9).
doi:10.1371/journal.ppat.1003219.g002
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All the twelve control challenged voles, culled at the end of the
experiment (810 d.p.i.) or found dead for intercurrent disease (two
voles, at 550 and 721 d.p.i.), were found PrPSc negative by
Western blot analysis.
CWD adapts to Bv109I with strikingly short survival times
In order to study the adaptation of CWD prions in Bv109I and
to compare more closely the biological properties of the various
CWD isolates, vole-passaged CWD isolates were further propa-
gated in Bv109I. On the second passage we observed a dramatic
decrease in the incubation times, with behavioural alterations
already evident at 25–28 d.p.i.. Following a short clinical phase all
CWD isolates produced strikingly short mean survival times of
between 34 and 44 d.p.i. (Table 2). Survival times were stable or
slightly shorter on third passage, with all Bv109I-adapted CWD
strains giving a survival time of ,35 d.p.i. (Table 2).
The neuropathological phenotype after the second and subse-
quent passages was similar to that observed on primary transmission
(Figure 2B), with lesion profiles showing a slight increase in cortical
involvement (Figure 2B). The pattern of brain PrPSc distribution by
PET-blot was the same in all groups, characterised by PrPSc
deposition mainly in the thalamus, substantia nigra, geniculate
nuclei, vestibular nuclei and the deep layers of the cerebral cortex
(Figure 4). Bv109I-adapted SS7B showed a marked neurodegener-
ation in all areas considered in lesion profiles, with the exception of
the cerebellar cortex. PET-blot showed abundant PrPSc, distributed
throughout the brain. Prominent immunolabelling was observed in
the cortices, septal nucleus, hippocampus, thalamus, superior
colliculi, geniculate nuclei and medulla oblongata.
Overall these data suggest that the same strain, designated
Bv109ICWD, was isolated from elk, mule deer and white-tailed deer.
Strain characterisation from Bv109I outliers suggests the
isolation of more than one prion component in primary
transmission
Two voles, designated CWD3outlier and CWD4outlier, which
developed clinical signs after unusually long times of 805 and
792 d.p.i. at primary transmission of CWD3 and CWD4 were
Figure 3. Western blot analysis of the PrPres level in the brain of CWD-affected voles. (A) Immunoblot of proteinase K–resistant PrPSc
(PrPres) from one original elk isolate (CWD1) and from voles infected with CWD1, 3 and 5. (B) Comparison of PrPres amount and glycoprofile between
Bv109I-adapted CWD and Bv109M-adapted sporadic CJD, sheep scrapie and cattle BSE, at third passage. Membranes were probed with SAF84.
Molecular size markers are shown in kilodaltons on the right.
doi:10.1371/journal.ppat.1003219.g003
Table 2. Survival times of Bv109I and Bv109M after subsequent passages of CWD.
Second passage Third passage Fourth passage
Donor (d.p.i.)
Survival time
(mean±SD)
Donor
(d.p.i.)
Survival time
(mean±SD) Donor (d.p.i.)
Survival time
(mean±SD)
Elk CWD1 181 3563 (10) 34 3763 (9) 34 3562 (7)
CWD2 173 3563 (6) 35 3462 (11)
CWD4 165 3461 (7) 39 3361 (6)
792 134, 169 134 5465 (8) 49 3362 (6)
60 3564 (6)
Mule deer CWD3 167 4061 (6) 32 3262 (6)
805 16468 (6) 176 4264 (8) 47 3461 (6)
White-tailed deer CWD5 146 4063 (8) 38 3460 (6)
CWD7 148 4263 (8) 38 3362 (6)
CWD8 149 4463 (7) 43 3463 (6)
Sheep SS7B 209 7364 (12) 71 6966 (12)
The number of animals in each group is reported in brackets. The survival times of voles used for vole-to-vole transmissions, indicated as ‘donors’, are shown.
doi:10.1371/journal.ppat.1003219.t002
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selected for supplementary strain typing. Second passages from
CWD3outlier and CWD4outlier gave much longer survival times
compared with CWD3 and CWD4 (Table 2). At subsequent
passages the survival time decreased progressively and CWD3outlier
and CWD4outlier were fully adapted only at the fourth passage
(Table 2). Interestingly, neuropathological assessment at the
second (data not shown) and third (Figure S2) passages showed
much less severe spongiform changes in the cortex and superior
colliculus than Bv109ICWD at ,35 d.p.i.. By the fourth passage,
the lesion profiles converged to Bv109ICWD (Figure S2) and the
survival time decreased to ,35 d.p.i.. These data suggest that the
Bv109ICWD strain was eventually isolated also from CWD3outlier
and CWD4outlier, although it required four subsequent passages to
emerge. The deviant neuropathological profile observed in
CWD3outlier and CWD4outlier at first passage was propagated for
at least two vole-to-vole passages, suggesting that a second CWD
strain was isolated in these outliers, which was progressively
outcompeted by the extreme rapidity of the Bv109ICWD strain.
Characterisation of Bv109ICWD
The infectious titre of Bv109ICWD was determined by endpoint
titration. Increasing survival times were observed with 1022 to 1025
dilutions, while dilutions higher than 1025 also produced a
decreasing attack rate (Figure 5). The infectious titre of Bv109ICWD
was 108,4 i.c. ID50 U g
21. The vast majority of diseased animals
succumbed within,100 d.p.i., and only 3 out of 44 voles developed
the disease later on, with unequivocal clinical signs (Figure 5). Thus
Bv109ICWD undergoes very fast replication kinetics, allowing high
prion titres to accumulate in a very short time.
To analyse the potential of Bv109ICWD to be amplified in vitro,
we performed PMCA experiments using 1/100 mixtures of
Bv109ICWD as seed and brain homogenates from Bv109I voles
as substrate. As already shown with other vole species [24],
Bv109ICWD was efficiently amplified already at the first PMCA
round (amplified products from rounds 4 to 13 are shown in
Figure S4). In order to verify whether Bv109ICWD infectivity was
Figure 4. Regional distribution, by PET-blot, of PrPres following
the third passage of CWD1, CWD3, CWD5 and sheep scrapie in
Bv109I. Coronal sections of the forebrain representing: telencephalon
(A), diencephalon (B), midbrain (C) and hindbrain (D). In the lower part
of the figure, the labelled coronal sections of negative control brain
from 150 days old Bv109I are shown: VP, ventral pallidum; NC,
neocortex; Hp, hippocampus; Th, thalamus; GN, geniculate nuclei; SN,
substantia nigra; ICN, interposed cerebellar nucleus; MO, medulla
oblongata.
doi:10.1371/journal.ppat.1003219.g004
Figure 5. End-point titration of Bv109ICWD infectivity in Bv109I. Triangles represent individual survival times. Voles that did not show signs of
infection after 450 d.p.i. are plotted in compressed form after the x axes break point. The mean survival times (days 6 standard deviation) and the
numbers of diseased/inoculated voles are indicated on the right of each chart.
doi:10.1371/journal.ppat.1003219.g005
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efficiently propagated during saPMCA and to study its biological
properties in comparison with the original Bv109ICWD, we
performed saPMCA experiments for 15 successive PMCA rounds
so that the original seed was diluted 1016-fold. This dilution was
such that only the newly generated PrPSc was theoretically present
in the final PMCA product. Groups of nine voles were inoculated
with 10-fold dilutions of either in vitro-generated Bv109ICWD
(designated Bv109ICWDPMCA) or the original Bv109ICWD used as
seed. Bv109ICWDPMCA induced terminal disease in 4262 d.p.i., a
survival time similar to that of the control Bv109ICWD inoculum
(3862 d.p.i.). The second passage of Bv109ICWDPMCA produced
disease in 3462 d.p.i.. The clinical phenotype and the lesion
profile of animals infected with Bv109ICWDPMCA, after primary
transmission and second passage, were indistinguishable from the
control group (Figure 6A). The type of PrPSc deposition and the
pattern of PrPSc distribution in the brain, analysed by IHC (not
shown) and PET-blot (Figure 6B), were also the same in
Bv109ICWDPMCA and Bv109ICWD. Overall, Bv109ICWD pro-
duced in vitro was highly infectious and faithfully maintained the
properties of the original Bv109ICWD strain.
Figure 6. Biological properties of in vitro-generated Bv109ICWD (Bv109ICWDPMCA). A) Lesion profiles of Bv109I infected with Bv109ICWDPMCA
following primary transmission (open circles) and second passage (closed diamonds), compared with Bv109I infected with Bv109ICWD (triangles).
Brain-scoring positions are described in Figure 2. B) Regional distribution, by PET-blot with SAF84 mAb, of PrPres in Bv109I infected with
Bv109ICWDPMCA following primary transmission and second passage compared with the control group (Bv109ICWD). Brain areas are as in Figure 4.
doi:10.1371/journal.ppat.1003219.g006
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Discussion
In the present study we investigated the susceptibility of Bv109I
and Bv109M to seven CWD isolates from three deer species and
found that these animal models are highly permissive to CWD,
showing 100% attack rate and mean survival times between 156
and 281 d.p.i.. A deepened transmission and characterization
study of CWD was carried out in Bv109I. The susceptibility of this
model appeared comparable to that of transgenic mice expressing
cervid PrP [6,7,9,10,11]. The reasons for such a high susceptibility
are unclear but apparently not related to a different expression of
PrPC. As a matter of fact, its expression level in Bv109I is
comparable to that of mouse and hamster (Figure S5). The
dramatic drop in survival time with vole-to-vole sub-passages
suggests that CWD still encounters a high transmission barrier in
Bv109I, implying that Bv109I permissiveness to CWD was not due
to the absence of transmission barrier, as observed in transgenic
mice expressing cervid PrP. Using Bv109M voles we have
previously shown that this species is permissive to a variety of
human and animal prion diseases. Studies aimed at investigating
the molecular basis of the susceptibility of bank voles to foreign
prions and their selective strain preferences suggested that two
asparagine residues at positions 150 and 170, specific to vole PrP,
might play a role [18,22,25]. Interestingly, cervid PrP also has
asparagine at residue 170, suggesting that sequence identity at
codon 170 might facilitate the transmission of CWD to Bv109I.
This interpretation is supported by the relative ease of transmission
of CWD to meadow voles [14], which also have asparagine at
positions 150 and 170, as well as by studies in MoPrP170N, 174T
transgenic mice [24,26] and by in vitro amplification of CWD by
PMCA [27].
A striking feature of Bv109I-adapted CWD was the short
incubation time of less than one month. In an earlier work, we
showed that bank voles and related rodent species have peculiarly
short survival times after infection with adapted prions, and
presumably support equally fast prion replication kinetics, possibly
due to the previously mentioned 150N–170N PrP residues [22].
This was also observed in vitro using Bv109M brain homogenates
as substrate for PMCA-driven prion replication [28]. Notwith-
standing this, our previous and on-going studies with Bv109M
have not shown evidence of ultra-fast strains such as Bv109ICWD,
and the fastest strains observed so far in voles show incubation
times of ,2 months [19, unpublished data). Transmission studies
of CWD to Bv109M have not yet completed but we have observed
that also CWD adapts to Bv109M with survival times longer than
Bv109ICWD (60–100 d.p.i.) (unpublished data). The short survival
time of Bv109ICWD is also unprecedented when compared with
those found in transgenic mouse models, in which PrP overex-
pression greatly fosters prion diseases [6,7,8,9,10,11]. Indeed, the
fastest rodent models reported so far, i.e. Tga20 [29], Tg52NSE
[30], Tg7 [31], Tg4053 [32] and Tg338 mice [33], express
several-fold higher PrP levels compared with wild-type mice and
have incubation periods at least twice as long as Bv109ICWD.
Interestingly, it was recently shown that TgS3581 mice overex-
pressing vole PrP encoding for Isoleucine at position 109, undergo
spontaneous prion disease and that it adapts to the same model
with mean survival time of 35 days [34]. These findings suggest
that the presence of Isoleucine at position 109 of the vole PrP plays
a specific role in determining the short survival time of
Bv109ICWD
In the present work we provide evidence that all the hallmarks
of TSEs were recapitulated within one month in bank vole CWD.
The finding that neurodegeneration and PrPSc deposition showed
a discrete brain distribution, involving specific neuronal popula-
tions such as those in the medulla and thalamus, might suggest that
Bv109ICWD replication primarily involves the so called clinical
target areas (CTAs) which, once colonised by prions, trigger the
clinical signs and death of the animals [35,36]. A recent study
showed that shorter time periods were needed to initiate the
clinical phase when the 127S scrapie strain primarily targeted
CTAs, as in intraperitoneally-inoculated Tg338 mice, compared
with intracerebrally-inoculated mice [37]. This was accompanied
by comparatively low levels of PrPres and infectivity in the brain
of ip-inoculated mice. In Bv109ICWD we also observed unusually
low levels of PrPres, compared with those observed in most of the
vole-adapted prion strains (Figure 3). However, by endpoint
titration we found unexpected high prion titres in Bv109ICWD,
108,4 i.c. ID50 U g
21, similar to those usually observed in standard
hamster and mouse-adapted scrapie strains, whose incubation
times are 3–10 times longer than Bv109ICWD. This implies that
Bv109ICWD undergoes extraordinarily fast replication kinetics in
Bv109I brain.
Several observations suggest that prion infectivity and
toxicity might be uncoupled [38,39,40] and these observations
are currently incorporated in a general model of prion replication
and toxicity [41]. According to this model, neurotoxicity is
mediated by a lethal PrP species, PrPL, which is distinct from
PrPSc, but its formation is catalysed during the autocatalytic
replication of PrPSc. Neurotoxicity may require a critical
PrPL concentration to be reached, which would depend on the
kinetics of prion propagation. The relative levels of toxicity
and infectivity are governed by the ratio of the initial rate of
PrPC conversion (which leads to the production of PrPL) to the rate
of its maturation into PrPSc. Thus fast prion replication in
Bv109ICWD might have triggered the production of high levels
of PrPL in short time periods, leading to rapid disease onset
and animal death. The low levels of PrPSc and the fast replica-
tion kinetics observed in Bv109ICWD are consistent with this
interpretation.
A recent work showed that in mice inoculated with the RML
scrapie strain the concentration of PrPC did not affect the overall
level of prion infectious titres at terminal disease, while it was
directly related to the incubation time, suggesting that the
production of PrPL is directly proportional to PrPC concentrations
[42]. Our observations with Bv109ICWD, i.e. the unusually short
survival time and the high prion infectious titre in a model that
does not overexpress PrPC, suggest that the kinetics of prion
propagation and toxicity are governed by mechanisms that cannot
be interpreted solely on the basis of the amount of available
substrate (PrPC).
The unique and easily distinguishable features of Bv109ICWD
prompted us to pursue its in vitro propagation by saPMCA.
Bv109ICWD PrPSc was indeed easily propagated in vitro, which
allowed us to produce Bv109ICWDPMCA PrPSc, theoretically
devoid of any PrPSc formed in vivo. Bv109ICWDPMCA was highly
infectious and faithfully reproduced the peculiar phenotype of
Bv109ICWD. These findings confirm that CWD prions can be
generated in vitro, as already demonstrated by others using
transgenic mice expressing cervid PrP [43,44,45,46] and prairie
voles [47]. Furthermore, given the unique characteristics of this
strain, it is extremely unlikely that their faithful maintenance
during saPMCA could have occurred by chance and our results
represent a convincing confirmation of other studies that have
already demonstrated the ability of PMCA to replicate prion
strains faithfully [44,45,47,48,49].
Elk, mule deer and white-tailed deer are the species most
affected by CWD. The homogeneous and peculiar phenotypes
observed in Bv109I inoculated with CWD isolates from these
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three cervid species indicate that the same CWD strain was
isolated from all species. Interestingly, Bv109ICWD was isolated
not only from natural cases of disease in elk (CWD1, 2 and 4)
and mule deer (CWD3), but also from white-tailed deer
experimentally inoculated with CWD-affected white-tailed deer,
mule deer and elk (CWD5, 7 and 8, respectively). Along with
previous findings in transgenic mice expressing cervid PrP
[6,9], and in keeping with the ease of indirect horizontal
transmission of CWD [50], these data suggest that the same
CWD strain circulates among different cervid species and
maintains its characteristics following interspecies transmission.
Recently, a large transmission study with elk and mule deer
isolates provided substantial evidence for two prevalent CWD
prion strains and suggested that individual CWD inocula might
contain mixtures of the two prion strains [11]. Interestingly, we
found similar evidence in at least two of the seven inocula
investigated, derived from elk and mule deer, although we were
unable to stabilize two different Bv109I-adapted CWD strains.
Indeed, on primary transmission of CWD2, CWD3 and CWD4
inocula we observed voles that developed clinical signs after
unusually long times, showing a slightly different neuropatho-
logical profile from that of voles with shorter survival times. A
sub-passage in Bv109I of two of these outliers induced a
survival time of 150–160 d.p.i. on second passage, compared
with 35–45 d.p.i. observed with all other sub-passages. Such a
long survival time might have depended on a low infectious
titre in the brain from outlier voles, although they showed
levels of PrPres similar to the other voles of their groups.
However this hypothesis is excluded when these results are
compared with the survival times observed in the endpoint
titration experiment, which showed that even 1025 dilution of
Bv109ICWD had a mean survival time ,80 d.p.i.. In addition,
the slightly deviant lesion profile observed in outlier voles was
preserved for 2 sub-passages, before both the survival time and
the neuropathological profile converged with the fast
Bv109ICWD strain. Overall, our findings strongly suggest that
a second CWD strain was propagated in vole outliers, which
was progressively outcompeted by the extremely rapid
Bv109ICWD strain. The ‘‘evanescent’’ presence of a second
strain might be also interpreted, according to the quasi species
nature proposed for prions [51], as the progressive elimination
of the less fitting conformers occurred following interspecies
transmission.
Here we demonstrate the high susceptibility of Bv109I to CWD,
which adds Bv109I to the portfolio of animal models useful for the
study of CWD strains. The unique properties of Bv109ICWD
provide exceptional opportunities to improve basic knowledge of
the relationship between PrPSc, neurodegeneration and infectivity.
The short survival time of Bv109ICWD, coupled with its high
infectious titre, offers useful advantages for titration studies, while
its unique clinico-pathological phenotype makes Bv109ICWD one
of the best options for studies aimed at investigating strain fidelity
in experimental conditions.
Materials and Methods
Ethics statement
Bv109I and Bv109M were obtained from the breeding colony at
the Istituto Superiore di Sanita` (ISS). The research protocol,
approved by the Service for Biotechnology and Animal Welfare of
the ISS and authorised by the Italian Ministry of Health, adhered
to the guidelines contained in the Italian Legislative Decree 116/
92, which transposed the European Directive 86/609/EEC on
Laboratory Animal Protection.
Samples and transmission experiments
Brain tissues from CWD affected elk (n = 3), mule deer (n = 1)
and white-tailed deer (n = 3) were used for primary transmissions.
Two isolates from elk, CWD1 and CWD2, were provided by the
United States Department of Agriculture (Dr. A.L. Jenny) and
carried the wild type PRNP genotype. The third elk isolate,
CWD4, was heterozygous methionine/leucine at codon 132. It
was provided by the University of Wyoming (Dr. J.E. Jewel) as the
mule deer isolate, CWD3, which was homozygous for serine at
codon 225. The three isolates from white-tailed deer derived from
an intracerebral experimental challenge [52]. All deer were
heterozygous glycine/serine at codon 96 and were challenged
with a white-tailed deer CWD isolate (CWD5, code 654 in the
original paper), a mule deer CWD (CWD7, code 643) or a elk
CWD (CWD8, code 677). Brain sample from a healthy elk was
also inoculated as negative control.
An Italian scrapie isolate from Sarda sheep (SS7B) carrying the
ARQ/ARQ genotype previously characterised into Bv109M [19],
was used for comparison.
Tissues were homogenised at 10% (wt/vol) in phosphate
buffered saline (PBS) and stored at 280uC. The PrPres amount
estimated by Western blot was comparable in all the homogenates
(data not shown).
Groups of eight-week-old Bv109I and Bv109M were inoculated
intracerebrally with 20 m of homogenate into the left cerebral
hemisphere, under ketamine anaesthesia (ketamine 0.1 mg/g). The
animals were examined twice a week until neurological signs
appeared, after which they were examined daily. Diseased animals
were culled with carbon dioxide at the terminal stage of the
disease, but before neurological impairment was such as to
compromise their welfare, in particular, their ability to drink and
feed adequately. Survival time was calculated as the interval
between inoculation and culling or death. After that, the brain was
cut parasagittally into two parts. The smaller portion was stored at
280uC and the larger one was fixed in formalin.
The inocula for the second and third passages were prepared, as
10% wt/vol homogenates in PBS, using the brain of one of the
first animals of each group that developed the disease. Supple-
mentary second and subsequent passages from two voles that
showed much longer survival times compared with the rest of their
groups (outliers) were also performed.
Titration of Bv109ICWD
The specific infectivity of Bv109ICWD was assessed in Bv109I by
end-point titration using tenfold dilutions of brain homogenates
from the third passage of CWD1 and calculated as ID50 U g
21
according to the Spearman and Ka¨rber method [53]. Survivors
were animals that survived until the end of the experiment
(450 d.p.i.) with no sign of infection, as assessed by Western blot.
The transmission rate was calculated as the ratio between voles
confirmed positive by Western blot and the number of voles
inoculated, excluding animals culled for intercurrent disease
before 30 d.p.i..
Histopathology
Histology, immunohistochemistry (IHC) and PET-blot analysis
were performed on formalin-fixed tissues as previously described
[16,19]. Briefly, brains were trimmed at standard coronal levels,
embedded in paraffin wax and cut at 6 mm for haematoxylin and
eosin staining, immunohistochemistry and PET-blot. Sections
were randomly mixed and coded for blind pathological assess-
ment. For the construction of lesion profiles, vacuolar changes
were scored in nine grey-matter areas of the brain on haematox-
ylin and eosin stained sections [16,54,55]. Vacuolation scores were
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derived from the examination of at least six voles per group. PET-
blot and IHC were performed as described in Di Bari et al. [19,26]
using the SAF84 mAb.
Western blot
CWD inocula (10% w/v homogenates in PBS) were added to
PBS/sarcosyl up to a final 2% sarcosyl (Sigma) concentration and
incubated for 20 min at room temperature before digestion with
proteinase K (200 mg/ml) for 1 hour at 37uC with gentle shaking.
Protease treatment was stopped with 3 mM PMSF.
Brain homogenates (10% w/v) from individual voles were
prepared in 100 mM Tris-HCl, pH 7.4, containing 2% sarcosyl,
incubated for 20 min at room temperature and then digested with
proteinase K (50 mg/ml) for 1 hour at 37uC with gentle shaking.
Protease treatment was stopped with 3 mM PMSF.
Electrophoresis and Western blotting were performed as
previously described [16]. Briefly, samples were denatured by
adding NuPage LDS Sample Buffer (Invitrogen, Carlsbad,
California, United States) and NuPage Sample Reducing Agent
(Invitrogen), and heated for 10 min at 90uC. After centrifugation
at 10,000 g for 5 min each sample was loaded onto 12% bis-Tris
polyacrylamide gels (Invitrogen). After electrophoresis and West-
ern blotting on PVDF membranes (Immobilon-P; Millipore,
Bedford, MA, USA), the blots were processed by SNAP i.d.
Protein Detection System (Millipore) in accordance with the
manufacturer’s instructions. Vole PrPres was detected using
monoclonal antibodies SAF84 (1.2 mg/ml; epitope at amino acids
163–169 of the bank vole PrP sequence) and 12B2 (2.4 mg/ml;
epitope at amino acids 89–93 of the sheep PrP sequence).
Horseradish peroxidase-conjugated anti-mouse immunoglobulin
(Pierce Biotechnology, Rockford, Illinois, United States) was used
as secondary antibody (1:13,000). The membranes were developed
using an enhanced chemiluminescence method (SuperSignal
Femto, Pierce). The chemiluminescence signal was detected using
the VersaDoc imaging system (Bio-Rad) and was quantified by
QuantityOne software (Bio-Rad).
Serial automated protein misfolding cyclic amplification
A vole brain from the third passage of CWD1 was
homogenised at 10% w/v in PBS and divided into two
aliquots. The first aliquot was used as a seed for saPMCA
while the second was used for bioassays. Substrates from
Bv109I voles were prepared as 10% brain homogenates in
conversion buffer (PBS, 0.15 M NaCl and 1% Triton X) and
saPMCA was performed as previously described [28] by
diluting 1:100 the seed into Bv109I substrate followed by one
round of PMCA using a Misonix 3000 Sonicator, with the
following settings: 20 seconds of sonication every 30 minutes for
24 hours (48 cycles of incubation/sonication); 200–250 watts
(potency 8) sonication power. For successive rounds of
saPMCA, the product of the previous round was diluted 1:10
into fresh substrate and subjected to a further PMCA round.
This procedure was repeated 14 times to reach a 10215 final
dilution of the initial CWD infected brain homogenate. The
detailed protocol for saPMCA has been published elsewhere
[56,57,58]. After each round, PrPres was evaluated by Western
blot (Figure S4). Given the risk of contamination that is
intrinsic for an ultrasensitive technique as PMCA [28], several
healthy Bv109I brain homogenates were processed, as negative
controls, in each round. Before each successive round, the
products of the previous round were analysed by Western blot
to confirm the amplification of Bv109ICWD and the negativity
of controls.
Supporting Information
Figure S1 Survival times of Bv109I and Bv109M follow-
ing primary transmission of CWD and sheep scrapie.
Outliers are visible among Bv109I inoculated with CWD2, 3 and
4; one outlier is visible among Bv109M with CWD1. Symbols
represent individual survival times. Bars indicate the median for
each group.
(TIF)
Figure S2 Lesion profiles of Bv109I inoculated with
outliers from CWD3 and CWD4. A) Lesion profiles of Bv109I
inoculated with the third passage of CWD3outlier (red line and
open circles) and CWD4outlier (green line and closed triangles). B)
Lesion profiles of Bv109I inoculated with the fourth passage of
CWD3outlier (red line and open circles) and CWD4outlier (as shown
in Table 2, two fourth passages were performed out from voles
culled at 49 and 60 d.p.i. in the third passage – identified with
green and green dashed lines respectively, and closed triangles) in
comparison with Bv109ICWD (black line and closed circles). Brain
areas are as in Figure 4.
(TIF)
Figure S3 Comparison of PrPres amount in Bv109I
inoculated with scrapie and Bv109ICWD. The amount of
PrPres in Bv109I inoculated with Bv109I-adapted sheep scrapie
(SS7B) and with Bv109ICWD was estimated by direct comparison
of brain homogenate dilutions. The homogenates were treated
with 50 mg/ml PK. Each sample was diluted in loading buffer
after the denaturation step. The original samples (1:1) were
loaded as 0.5 mg of equivalent brain tissue. Membrane was
probed with SAF84. Molecular weight markers are shown on the
right.
(TIF)
Figure S4 In vitro amplification of Bv109ICWD. Western
blot of Bv109ICWD following saPMCA. Bv109ICWD was diluted
10-fold into healthy Bv109I brain homogenate and submitted to a
round (48 cycles) of PMCA. The amplified material was diluted
10-fold into healthy brain homogenate repeating this procedure to
reach a 10213 dilution of Bv109ICWD. Amplified samples from
rounds 4 to13 were digested with 80 mg/ml of proteinase K and
analysed by Western blot using monoclonal antibody D18.
Control: Normal Bv109I brain homogenate.
(TIF)
Figure S5 Comparison of PrPC levels in the brain of
voles, mouse and hamster. The amount of PrPC in the brain
of Bv109M, Bv109I, RIII mice and hamster was assessed by direct
comparison of brain homogenate dilutions (1:1, 1:2, 1:4). Brain
homogenates were loaded as 0.1 mg (1:1), 0.05 mg (1:2) and
0.025 mg (1:4) tissue equivalents. Membrane was probed with
12B2.
(TIF)
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